[
    [
        {
            "time": "",
            "original_text": "康泰生物(300601)：五价轮状病毒疫苗临床获批 研发管线再获完善",
            "features": {
                "keywords": [
                    "康泰生物",
                    "五价轮状病毒疫苗",
                    "临床获批",
                    "研发管线"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物(300601)：五价轮状病毒疫苗临床获批 研发管线再获完善",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司获得腺病毒载体新冠疫苗在巴基斯坦、印度尼西亚商业化权利",
            "features": {
                "keywords": [
                    "康泰生物",
                    "腺病毒载体新冠疫苗",
                    "巴基斯坦",
                    "印度尼西亚",
                    "商业化权利"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗",
                    "国际合作"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司获得腺病毒载体新冠疫苗在巴基斯坦、印度尼西亚商业化权利",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司相关重组均已取得有权主管部门的批复，履行了法定程序",
            "features": {
                "keywords": [
                    "康泰生物",
                    "重组",
                    "主管部门批复",
                    "法定程序"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "企业合规"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司相关重组均已取得有权主管部门的批复，履行了法定程序",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司自主研发的13价肺炎球菌多糖结合疫苗2021年11月已在国内上市销售",
            "features": {
                "keywords": [
                    "康泰生物",
                    "13价肺炎球菌多糖结合疫苗",
                    "自主研发",
                    "国内上市销售"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗",
                    "自主研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司自主研发的13价肺炎球菌多糖结合疫苗2021年11月已在国内上市销售",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司四联疫苗、23价肺炎球菌多糖疫苗、乙肝疫苗等取得了部分国家出口的证书",
            "features": {
                "keywords": [
                    "康泰生物",
                    "四联疫苗",
                    "23价肺炎球菌多糖疫苗",
                    "乙肝疫苗",
                    "出口证书"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗",
                    "国际市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司四联疫苗、23价肺炎球菌多糖疫苗、乙肝疫苗等取得了部分国家出口的证书",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司产品管线储备丰富，研发能力和生产规模位居国内疫苗行业前列",
            "features": {
                "keywords": [
                    "康泰生物",
                    "产品管线",
                    "研发能力",
                    "生产规模",
                    "疫苗行业前列"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗",
                    "研发能力"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司产品管线储备丰富，研发能力和生产规模位居国内疫苗行业前列",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]